Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0IKOGW
ADC Name	Omalizumab-amanitin 1
Synonyms	Omalizumab Amanitin1 Click to Show/Hide
Organization	Heidelberg Pharma AG
Drug Status	Investigative
Indication	In total 2 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Pancreatic ductal adenocarcinoma [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	1
	3D MOL	2D MOL
Antibody Name	Omalizumab		Antibody Info
Antigen Name	High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A)		Antigen Info
Payload Name	Beta-amanitin		Payload Info
Therapeutic Target	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)		Target Info
Linker Name	Omalizumab-Amanitin1 linker
Conjugate Type	Random conjugation through nucleophilic lysines.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	> 100	nM	CVCL_0031	Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50)	> 100	nM	CVCL_0237	Pancreatic ductal adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100.00 nM	Positive EPCAM expression (EPCAM+++/++)
Method Description	Cells were added in 50 ul at a density of 50,000 per ml in the experiments with ADCs and at a density of 20,000 per ml in the experiments with huHEA125-Amanitin3. Plates were incubated in a humidified atmosphere at 37°C and 5% CO₂ for 72 or 96 h. At 20 h before the end of the assay, 1 uCi of H-thymidine was added.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100.00 nM	Positive EPCAM expression (EPCAM+++/++)
Method Description	Cells were added in 50 ul at a density of 50,000 per ml in the experiments with ADCs and at a density of 20,000 per ml in the experiments with huHEA125-Amanitin3. Plates were incubated in a humidified atmosphere at 37°C and 5% CO₂ for 72 or 96 h. At 20 h before the end of the assay, 1 uCi of H-thymidine was added.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237

References

Ref 1	Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy.